Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Efficacy of Engineered T-Cell Receptor (TCR) Therapies in PDX Mouse Models of Melanoma

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Efficacy of Engineered T-Cell Receptor (TCR) Therapies in PDX Mouse Models of Melanoma

Evaluating Engineered TCR-T Cell Efficacy in Patient-Derived Xenograft Models of Melanoma

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

Technical Question Franklin Biolabs Response
How do you ensure the PDX model retains the heterogeneity of the original patient tumor? We employ low-passage tumor fragments for implantation. This preserves the original tumor architecture, cellular diversity, and tumor microenvironment (TME) components, providing a more accurate substrate for evaluating TCR-T cell infiltration and activity compared to dissociated cell models.
What are the key endpoints for assessing TCR-T cell efficacy in a melanoma PDX model? Primary endpoints include tumor growth inhibition (TGI) and regression analysis via caliper measurements. Secondary endpoints involve flow cytometry to quantify T-cell persistence and phenotype within the tumor and spleen, alongside multiplex IHC and Histology to assess tumor cell killing and immune infiltration.
How is the human immune component reconstituted in these models? Our studies utilize severely immunodeficient strains engrafted with human hematopoietic stem cells (HSCs) or peripheral blood mononuclear cells (PBMCs). This establishes a humanized immune system capable of supporting the persistence, expansion, and effector function of the administered human TCR-T cells.
What GxP-compliant data is generated for an IND submission? All in vivo study conduct, data collection, and analysis are performed within a GxP framework. The final IND-enabling data package includes audited study reports detailing efficacy, T-cell kinetics, and non-target tissue biodistribution, which are structured to support regulatory review.

Evaluating engineered T-cell receptor (TCR) therapies requires in vivo models that accurately predict clinical outcomes. Patient-derived xenograft (PDX) models of melanoma, particularly when paired with a humanized immune system, offer a high-fidelity platform to assess efficacy and de-risk clinical candidates. This approach moves beyond the limitations of traditional cell line-derived models by preserving the complex tumor microenvironment, providing more translatable data on T-cell infiltration, persistence, and anti-tumor activity for IND-enabling studies.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

De-Risking TCR Candidates with Clinically Relevant In Vivo Models

The therapeutic potential of an engineered TCR-T cell is directly linked to its ability to recognize a specific peptide-MHC complex on tumor cells and execute its effector function within a complex, often immunosuppressive, tumor microenvironment. Standard cell line-derived xenograft (CDX) models frequently lack the architectural and cellular heterogeneity of human tumors, leading to efficacy data that may not translate to the clinic.

PDX models established from patient melanoma samples overcome this limitation. By maintaining the native TME, these models provide a superior system for assessing key performance attributes of a TCR-T cell candidate, including:

  • Tumor Infiltration: Ability to traffic to and penetrate a solid tumor mass.

  • On-Target Efficacy: Potency of tumor cell lysis in a complex environment.

  • In Vivo Persistence: Longevity and functional stability of the T-cell product post-infusion.

Strategic Principles for Predictive Model Selection

The core principle for generating a decision-useful dataset is selecting a model system that recapitulates key aspects of human biology. For instance, work developing advanced gene therapy vectors has shown that engineering a payload for superior biological function is a viable strategy for increasing therapeutic efficacy [PMID: 25023731]. This concept directly applies to the iterative design and selection of TCR constructs with optimal affinity and specificity.

Studies leveraging humanized systems have demonstrated their power in producing significant and translatable outcomes [PMID: 22985273]. Applying this principle to cell therapy, the use of PDX models engrafted with a human immune system is a fundamental component for evaluating a human T-cell therapy.

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Integrated Study Design for IND-Enabling Data

A robust preclinical efficacy program is executed in our >100,000 sq ft GxP-compliant facility, designed to support an average 18-24 month IND timeline. Since the Franklin Biolabs brand launch in 2024, programs managed by our scientific leadership have maintained a 100% IND success rate dating back to 2019.

A typical TCR-T cell efficacy study in melanoma PDX models integrates several key phases:

  • Model Development: Selection and expansion of a well-characterized, low-passage melanoma PDX line.

  • Humanization: Engraftment of immunodeficient hosts with human CD34+ HSCs.

  • Efficacy Assessment: Dosing with the TCR-T cell product and monitoring of tumor volume.

  • Pharmacodynamic Analysis: Terminal collection of tumor and tissues for Histology and flow cytometry to confirm T-cell activity and biodistribution.

Commitment to Animal Welfare

All in vivo studies are conducted in strict accordance with protocols approved by our Institutional Animal Care and Use Committee (IACUC). We adhere to the “3Rs” (Replacement, Reduction, and Refinement) as a core component of our animal welfare program, which is fully accredited by AAALAC International and registered with the USDA.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities